Teva snags MicroDose; Valeant selling $2 billion in shares; Mylan sued by Pfizer, Merck, AbbVie;

 @FiercePharma: Valeant to sell $2B worth of stock to finance Bausch + Lomb buyout, plus issue $7.5B in debt. More | Follow @FiercePharma

 @EricPFierce: India's Roselabs sees lots of upside in prefilled syringes for the Indian market. Story | Follow @EricPFierce

 @CarlyHFierce: Bristol-Myers makes another emerging markets move with Simcere partnership in China. Yesterday's story | Follow @CarlyHFierce

> Teva Pharmaceutical ($TEVA) will pay $40 million in upfront cash and up to $125 in contingent payments to get drug-delivery specialist MicroDose Therapeutx to expand its respiratory business. Story

> A prospectus says Valeant Pharmaceuticals ($VRX) intends to sell about $2 billion worth of shares to help finance its $8.7 billion acquisition of Bausch + Lomb. Story

> Pfizer ($PFE), Merck ($MRK) and InSite Vision Inc. are all suing Mylan Pharmaceuticals ($MYL) for infringing patents with its plan to manufacture a generic version of their eye drug AzaSite. Report

> AbbVie ($ABBV) also is suing Mylan Pharmaceuticals for stepping on three patents with it plan to make a copycat version of the HIV drug Norvi. Report

> Two independent reviews of Medtronic's ($MDT) controversial bone product Infuse indicate it works as well as traditional bone grafts but may have more risks. Story

> South Africa's Aspen Pharmacare has offered to buy GlaxoSmithKline's ($GSK) older thrombosis drug brands, Arixtra and Fraxiparine, for an undisclosed amount and pick up a plant in France in the process. Story

Medical Device News

 @FierceMedDev: Exact raising $63.7M on rocky road to FDA approval. News | Follow @FierceMedDev

 @DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. More | Follow @DamianFierce

 @MichaelGFierce: Check out our new FierceBiotech LinkedIn page... and sign up to join the discussion! LinkedIn group page | Follow @MichaelGFierce

> Boston Scientific targets FDA with brain-stim trial. Story

> Endologix endures FDA deadly warning over recall. Item

> Globus owes $16M in J&J patent suit. Report

Biotech News

 @FierceBiotech: Analysis: Big Pharma R&D demonstrates a woeful lack of innovation. News | Follow @FierceBiotech

 @JohnCFierce: AOP spins off its 80% stake in Activartis (cancer vaccines) after Elan shareholders reject takeover bid. Release | Follow @JohnCFierce

 @RyanMFierce: In $247M Transition deal, Eli Lilly is reeling in a diabetes drug candidate that it had spun off (sort of): Yesterday's item | Follow @RyanMFierce

> R&D cutbacks loom at Millennium's Cambridge ops. Item

> Teva Pharma breaks M&A silence with bite-sized MicroDose buyout. Report

> AstraZeneca picks Cambridge site as ground zero for R&D reinvention. News

> Royalty's $8B offer wilts after Elan prevails in blocking bid. Article

Biotech Research News

 @EmilyMFierce: Have you joined the @FierceBiotech LinkedIn group yet? Connect with biotech colleagues and join the discussion: Join now | Follow @EmilyMFierce

> Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies. Report

> New genetic mutations found in families with early-onset Alzheimer's. Item

> Inovio says H7N9 bird flu vaccine effective in mice. Story

> Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. More

Pharma Manufacturing News

> French plant part of proposed GSK, Aspen deal. Item

> Roselabs taps growth of prefilled syringe in India. Report

> City forecloses on Indiana insulin plant it helped fund. Article

> Eisai adding packaging facility to U.K. plant. More

And Finally... A new study says that Canada's public drug plans fall far short of many other countries in providing access to new treatments. Story

Suggested Articles

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

After Trump's "Buy American" executive order for essential medicines, the pharma industry is pushing back.

The U.S. is slamming the brakes on its $765 million loan to Kodak amid insider trading allegations and questions about its fitness for the job.